The Effect of Oral 17β-estradiol on Various Cardiovascular Atherosclerotic Indices in Postmenopausal Women: Does Chemical Structure Make a Difference? by Rowan, Britany C.
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
8-15-2009
The Effect of Oral 17β-estradiol on Various
Cardiovascular Atherosclerotic Indices in
Postmenopausal Women: Does Chemical
Structure Make a Difference?
Britany C. Rowan
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Rowan, Britany C., "The Effect of Oral 17β-estradiol on Various Cardiovascular Atherosclerotic Indices in Postmenopausal Women:
Does Chemical Structure Make a Difference?" (2009). School of Physician Assistant Studies. Paper 147.
The Effect of Oral 17β-estradiol on Various Cardiovascular Atherosclerotic
Indices in Postmenopausal Women: Does Chemical Structure Make a
Difference?
Abstract
Background: Estrogen has, in the past, been widely recognized as an endogenous hormone that aids in the
prevention of cardiovascular disease in postmenopausal women. However, conjugated equine estrogen with or
without sequentially administered medroxyprogesterone, was demonstrated to provide no benefit in the
prevention of cardiovascular disease and may in fact, aid in the progression of atherosclerotic disease in
women on this type of hormone replacement therapy. More randomized controlled trials have been
conducted recently to examine the effect of oral 17β-estradiol as opposed to conjugated equine estrogen, on
the progression of atherosclerotic disease in postmenopausal women.
Objective: To determine whether oral 17β-estradiol with or without sequentially administered progestogen
therapy has an effect on the progression and/or prevention of cardiovascular disease in postmenopausal
women.
Study Design: Systematic review of the available medical literature.
Methods: An exhaustive systematic review of the medical literature was conducted using, MEDLINE,
EBSCOhost, and EBMR Multifile using the keywords “estrogen replacement therapy” and “cardiovascular
diseases.” Trials were only included in this review if published after 2001 and if the trial was randomized and
controlled. Studies were rated using the Jadad criteria, and only studies with a Jadad score of 3 or higher were
included in this review.
Results: Overall it was found that in three studies atherosclerotic risk was decreased in women on HRT, in
three studies atherosclerotic risk was increased in women on HRT, and one study indicated no slowing in
progression of atherosclerosis but decreased risk for cardiovascular disease by improving lipid profiles. It is
important to note that all of the studies examined in this systematic review demonstrated a decrease in
cardiovascular risk in patients taking HRT when the endpoint measured was a serum biochemical marker. The
studies that demonstrated an increased risk for cardiovascular disease in women taking HRT measured
endpoints including percent coronary or carotid artery stenosis.
Conclusion: Estrogen replacement therapy using 17β-estradiol appears to reduce multiple biochemical
endpoints for cardiovascular disease risk including improving lipid profiles and decreasing inflammation.
However, 17β-estradiol does not have a positive effect on the progression of atherosclerosis in the carotid or
coronary arteries. Therefore, 17β-estradiol may reduce cardiovascular disease risk but evidence does not
suggest that this improvement in lipid profiles and inflammation actually affects atherosclerosis progression.
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Abstract   
 
Background:  Estrogen has, in the past, been widely recognized as an endogenous 
hormone that aids in the prevention of cardiovascular disease in postmenopausal women.  
However, conjugated equine estrogen with or without sequentially administered 
medroxyprogesterone, was demonstrated to provide no benefit in the prevention of 
cardiovascular disease and may in fact, aid in the progression of atherosclerotic disease in 
women on this type of hormone replacement therapy.  More randomized controlled trials 
have been conducted recently to examine the effect of oral 17β-estradiol as opposed to 
conjugated equine estrogen, on the progression of atherosclerotic disease in 
postmenopausal women. 
 
Objective: To determine whether oral 17β-estradiol with or without sequentially 
administered progestogen therapy has an effect on the progression and/or prevention of 
cardiovascular disease in postmenopausal women.  
 
Study Design:  Systematic review of the available medical literature. 
 
Methods:  An exhaustive systematic review of the medical literature was conducted 
using, MEDLINE, EBSCOhost, and EBMR Multifile using the keywords “estrogen 
replacement therapy” and “cardiovascular diseases.”  Trials were only included in this 
review if published after 2001 and if the trial was randomized and controlled.  Studies 
were rated using the Jadad criteria, and only studies with a Jadad score of 3 or higher 
were included in this review. 
 
Results:  Overall it was found that in three studies atherosclerotic risk was decreased in 
women on HRT, in three studies atherosclerotic risk was increased in women on HRT, 
and one study indicated no slowing in progression of atherosclerosis but decreased risk 
for cardiovascular disease by improving lipid profiles.  It is important to note that all of 
the studies examined in this systematic review demonstrated a decrease in cardiovascular 
risk in patients taking HRT when the endpoint measured was a serum biochemical 
marker.  The studies that demonstrated an increased risk for cardiovascular disease in 
women taking HRT measured endpoints including percent coronary or carotid artery 
stenosis.   
 
Conclusion: Estrogen replacement therapy using 17β-estradiol appears to reduce 
multiple biochemical endpoints for cardiovascular disease risk including improving lipid 
profiles and decreasing inflammation.  However, 17β-estradiol does not have a positive 
effect on the progression of atherosclerosis in the carotid or coronary arteries.  Therefore, 
17β-estradiol may reduce cardiovascular disease risk but evidence does not suggest that 
this improvement in lipid profiles and inflammation actually affects atherosclerosis 
progression.   
 
Keywords:  Estrogen replacement therapy, conjugated equine estrogen, 17β-estradiol, 
medroxyprogesterone, progestin, progesterone, progestogen 
 3 
Acknowledgements 
 
 
 To Chris, my wonderful husband.  I wouldn’t be where I am today without your 
love and support.  Thank you for always believing in me and encouraging me to reach 
farther.  The end is worth it. 
 
 To my family: Thank you for every word of encouragement and prayer for 
perseverance.  I can’t imagine being part of a more wonderful family 
  
 To The Landolt family, my Portland family.  I don’t know what I would do 
without you all.   
 4 
 
Table of Contents 
 
 
Biography …..….…………….……………………………………………………………1 
 
Abstract ….……..…………..…………………………………………………………......2 
 
Acknowledgements …...………………...………………………………………………...3 
 
Table of Contents …...……………..……………………………………………………...4 
 
List of Tables …...…….…………….……………………………………………….........5 
 
List of Abbreviations.……....…………….……………………………………………….5 
List of Appendices ….………..………..………………………………………………….5 
Introduction and Background…………….…………………………..…………………...6 
  
Methods ……………..………………………..……………………….………………….7 
 
Results ….………………..……………………………..………………………………...8  
 
Discussion………………………..……....………………………………………………14   
 
Conclusion……………………………………………………………………………….16    
 
Tables …………..…...…………………………………………………………………...17 
 
Appendix ………....…………………………………………………….…………….....19 
 
References ………....….….……..………………………………………………………20 
 
 
 
 
 
 
 
 
 
 
 
 5 
List of Tables 
 
Table 1:       Comparison of trials examining 17β-estradiol for hormone replacement  
  therapy in healthy, postmenopausal women 
 
Table 2:     Comparison of trials examining 17β-estradiol for hormone replacement  
  therapy in postmenopausal women with pre-existing cardiovascular  
  disease 
.   
 
 
List of Abbreviations 
 
WHI……………………………………………………….……Women’s Health Initiative 
 
CEE…………………………………………………………..Conjugated equine estrogens 
 
HRT.......................................................................................Hormone replacement therapy 
 
FSH…………………………………………………..………Follicle stimulating hormone 
 
LDL………………………………………………….……………Low density lipoprotein 
 
SAC……………………………………………….…………Systemic arterial compliance 
 
PWV……………………………………………………………..…….Pulse wave velocity 
 
FMD………………………………………………….…………….Flow mediated dilation 
 
ADMA………………………………………………….…..Asymmetric dimethylarginine 
 
MCP-1……………………………………………….Monocyte chemoattractant protein-1 
 
WELL-HART…………….Women’s Estrogen-Progestin Lipid Lowering Atherosclerosis  
         Regression Trial 
 
ACOG………………………...…………..American Committee on Gynecologic Practice 
 
 
 
List of Appendices 
 
Appendix A………………………..….........................Description of.Jadad Score Criteria
 6 
The Effect of Oral 17β-estradiol on Various Cardiovascular Atherosclerotic 
Indices in Postmenopausal Women: Does Chemical Structure Make a 
Difference1 
 
Introduction 
 
 A great deal of research has been generated in recent years revolving around the issue of the 
safety and efficacy of hormone replacement therapy for postmenopausal women.  One aspect of the 
issue that has been of intense debate, is whether hormone replacement therapy has an effect on either 
the prevention or progression of cardiovascular disease in postmenopausal women, and more 
specifically, whether this type of therapy has a deleterious effect on the cardiovascular health of 
women taking hormone replacement therapy. 4 Prior to the publication of the findings of the landmark 
Women’s Health Initiative (WHI)5 study in 2002, it was widely believed and accepted that estrogen 
had a cardioprotective effect6, though the mechanism by which estrogen produced this effect was not 
well understood4.  However, the findings of the WHI study demonstrated that women taking hormone 
replacement therapy using conjugated equine estrogen (CEE), with or without sequentially 
administered medroxyprogesterone for progesterone replacement, not only did not receive 
cardioprotection, but were possibly at an increased risk for atherosclerotic disease compared to the 
study participants taking placebo5.  Since 2002, many studies have been done to address the issue of 
whether the  increased risk of atherosclerotic disease in patients taking hormone replacement therapy 
demonstrated by the WHI study, applies across the board to women of various ages and various stages 
of menopause.  It is not clearly understood whether this risk factor can be extrapolated to women using 
various routes of estrogen administration including oral, transdermal, and vaginal administration, and 
whether, sequentially administered progestin or progesterone therapy decreases the potential 
cardioprotective benefit of estrogen6.  Another question that remains without a clear answer is whether 
using estrogen that is chemically and structurally identical to endogenously produced estrogen, 17β-
estradiol, for hormone replacement therapy, has a similar effect on the prevention and/or progression 
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of cardiovascular and atherosclerotic disease as CEE, which has a chemical structure that is not 
molecularly identical to naturally produced estrogen.  The aim of this systematic review is to examine 
the available medical literature published since 2001 to determine the effect of oral 17β-estradiol in 
women using this type of hormone replacement therapy, with or without sequentially administered 
progestogen therapy, on various markers and indices of atherosclerotic disease. 
Materials and Methods 
 A comprehensive search of the medical literature was conducted using various search 
modalities including MEDLINE, EBSCOhost, and EBMR Multifile and using the keywords “estrogen 
replacement therapy” and “cardiovascular diseases.”  Inclusion criteria for this review were all English 
language randomized controlled trials published after 2001 which included perimenopausal and 
postmenopausal women and the use of only oral 17β-estradiol for hormone replacement therapy, be it 
with progestogen therapy or without.  The studies included, followed women on estrogen using various 
types of progestogen therapy, mainly for protection against endometrial hyperplasia in women with 
intact uteri.  Studies were also included in this review regardless of the method of confirming 
menopause in the study participants and regardless of the participants’ stage of menopause.  The 
participants were included even if they had preexisting cardiovascular disease.  Studies using various 
endpoints for cardiovascular or atherosclerotic disease were examined in this review, including any 
biochemical marker generally regarded to contribute to inflammatory or atherosclerotic cardiovascular 
disease.  Other endpoints that are considered to be markers for cardiovascular disease, including 
average percent coronary artery stenosis and carotid intima-media thickness, were addressed in this 
review.   Studies which examined transdermal or vaginal estrogen replacement were excluded from 
this review. 
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 The studies were subsequently rated and assessed for quality using the Jadad criteria.  (For a 
detailed description of the Jadad criteria please see Appendix A).  The results of the remaining studies 
were then compiled and examined. 
Results 
 
 A total of 7 articles which met all of the inclusion and exclusion criteria were examined in this 
review (See Tables 1 and 2).  The average sample size was approximately 142, with the largest group 
studied consisting of 321 postmenopausal women, and the smallest group consisting of fifty one.  The 
shortest study lasted twelve weeks, and the longest followed study participants for a median of 3.3 
years.  All studies included in this review were randomized, controlled trials.  Three trials were double-
blinded, one was observer-blinded, and in three, neither participants nor observers were blinded.  All 
studies compared women on hormone replacement therapy (HRT) to participants on placebo pills, 
except one study, which compared HRT patients to patients not taking any pills.  All study participants 
receiving therapy were given oral 17β-estradiol, however in four studies participants received 17β-
estradiol as a dose of 1 mg daily and in three studies participants received 17β-estradiol 2 mg daily.  
Only one study examined study participants taking unopposed 17β-estradiol, and the remainder of the 
studies used 17β-estradiol replacement therapy with or without sequentially administered progestagen 
therapy, according to certain conditions individually outlined in each study.  The overall average age 
of the women participants in all of the studies examined in this review is 58 years of age.  However, 
the age of participants ranged from approximately 40 to 75 years of age.  Each study used its own 
method for determining the definition of “postmenopausal.” These methods ranged from determining 
minimum follicle stimulating hormone (FSH) serum concentrations, maximum estradiol serum 
concentrations, or establishing a minimum length of time since the last menstrual period. Three of the 
seven studies, examined women with a clinically documented increased risk for cardiovascular disease 
and in two of the studies, participants concomitantly received lipid-lowering medications if low density 
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lipoprotein (LDL) levels matched a certain criterion outlined in the study for determining 
hyperlipidemia.  The remaining four studies were of healthy women with no pre-existing 
cardiovascular disease.  Accordingly, the use of 17β-estradiol as both primary and secondary 
prevention for cardiovascular and atherosclerotic disease was considered in this review.  Since each 
study in this review included different endpoints, inclusion and exclusion criteria, and management of 
comorbid medical conditions in the study participants, each will be discussed individually with 
particular attention to similarities and differences.   
 Four studies examined 17β-estradiol replacement therapy in healthy women without pre-
existing cardiovascular disease.  Hodis, et al examined 222 postmenopausal women, 45 years of age or 
older with mean age of 62.2 years of age, for a length of two years, in the Estrogen in the Prevention of 
Atherosclerosis (EPAT) trial.7  This study received a Jadad score of 5.  Postmenopausal status in this 
study was confirmed by the presence of a serum estradiol level of <20 pg/mL.  The participants 
received unopposed 1 mg 17β-estradiol therapy daily.  Women also received dietary counseling and 
hydroxymethylglutaryl coenzyme-A reductase inhibitors therapy if LDL cholesterol level exceeded 
160 mg/dL.  The primary trial endpoint was the rate of change of intima-media thickness in the right 
distal common carotid artery measured with B-mode ultrasound.7  However, other endpoints were also 
examined including lipid parameters, and laboratory indices of carbohydrate metabolism.  Results 
demonstrated that subclinical atherosclerosis progressed more slowly in the group receiving HRT as 
opposed to the placebo group (P=0.046).  Laboratory values assessed in this study showed a significant 
increase in triglyceride (P=0.006) and HDL (P<0.001) levels in the estradiol group compared with the 
placebo group, as opposed to a significant decrease in LDL (P=0.001), insulin (P=0.01), and 
hemoglobin A1C (0.007) levels in the estradiol versus control groups.  Overall, atherosclerosis 
progressed more slowly in participants using HRT than those on placebo.  Results of this study were 
also analyzed after stratifying participants to those receiving lipid lowering medications and those not 
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receiving lipid lowering medications, and the slowing of atherosclerosis progression was actually 
greatest in those participants not receiving any lipid lowering medications (P=0.046). 
 Teede, et al8 also examined healthy women without preexisting cardiovascular disease in a 
double-blinded randomized, placebo-controlled study that received a Jadad score of 5.  The length of 
this study was also two years, however, only fifty nine women were examined and fifteen of them 
withdrew before completion of the study.  Patients were treated for medical issues diagnosed during 
the study; however neither the treatment type nor parameters were discussed in the study.  The average 
age of the participants was sixty one years of age, and all participants were at least two years post 
menopause as determined by self-reporting.  Therapy consisted of 2 mg 17β-estradiol daily plus 
progestogen in the form of norethisterone 1 mg versus placebo.  Endpoints measured included lipid 
profiles and indices of arterial function including systemic arterial compliance (SAC), a measure of the 
mechanical properties of the arteries, pulse wave velocity (PWV), a measure of arterial stiffness, and 
endothelial function, including flow-mediated vasodilation (FMD).  All parameters are well-
established positive risk factors for cardiovascular disease.8  Results of this study demonstrated no 
statistically significant reduction in lipid parameters in the treatment versus placebo group except for a 
statistically significant decrease in lipoprotein a (P=0.006) in the treatment group when compared to 
placebo.  However, this study was underpowered to detect differences in lipid profiles.  No statistically 
significant change in SAC, PWV, or FMD and therefore no positive effect on arterial compliance, 
endothelial function, or cardiovascular risk were demonstrated by this study.   
 Thijis, et al 9 studied sixty women without preexisting cardiovascular disease who were 
postmenopausal, normotensive, and nonhysterectomized. The study design was prospective, 
randomized, and placebo-controlled, but only partially blinded—observers were aware of study 
medications.  Therefore, this study only received a Jadad score of 3.  All participants were between 
forty five and sixty years of age with an average age of 52.2 years.  All had been amenorrheic for at 
least six months but for no more than five years and postmenopausal status was determined by 
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laboratory measurement of FSH of > 20 IU/L and serum estradiol < 150 pmol/L.  Participants were 
treated for only twelve weeks with 2 mg micronized 17β-estradiol daily, unopposed or sequentially 
combined with progestogen therapy using either trimegestone 0.5 mg daily or dydrogesterone 10 mg 
daily versus placebo.  Since activation of platelets is accompanied by antigenic changes on their 
surface,9 endpoint measurement was for three of these parameters of antigenic change indicating 
platelet activation including Von Willebrand factor receptor, P-selectin, and Glycoprotein 53.  Factors 
that influence platelet activation are widely regarding as causing an increase for risk of cardiovascular 
events.9  This study demonstrated no statistically significant change in Von Willebrand factor among 
the three groups, however a statistically significant increase in P-selectin was detected among the 
unopposed 17β-estradiol as well as 17β-estradiol plus progestogen treatment groups (P=0.04 for both).  
An increase in glycoprotein 53 (P=0.04) was also noted in the 17β-estradiol plus progestogen group 
but not the unopposed estradiol treatment group.  The results of this study suggest that 17β-estradiol 
therapy may increase the risk of cardiovascular events by increasing platelet activation.   
 The last study which examined women without preexisting cardiovascular disease was the 
study conducted by Post et al.10  Post et al studied the effect of HRT on asymmetric dimethylarginine 
(ADMA), which is an endogenous inhibitor of nitric oxide synthase, thus a known risk factor for 
cardiovascular events.  The study design was a randomized, placebo-controlled, prospective trial which 
received a Jadad score of 3.  All study participants were between the ages of forty five and sixty, with 
an average age of 52.2 years.  Sixty early postmenopausal, nonhysterectomized women were included.  
Participants must have been amenorrheic for six months to five years with a serum FSH level of > 20 
IU/L and serum estradiol < 150 mL.  Participants received 2 mg 17β-estradiol daily unopposed, or with 
either 10 mg dydrogesterone or 0.5 mg trimegestone daily for progestogen therapy.  Results of this 
study, showed that 17β-estradiol in combination with progestogen therapy, significantly lowered 
ADMA levels more than unopposed estradiol therapy or placebo. 
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 The remaining three studies all examined study participants with clinically established 
preexisting cardiovascular disease or cardiovascular risk factors.  Angerer et al3 conducted a 
randomized, placebo-controlled, observer blinded trial of 321 postmenopausal women that received a 
Jadad score of 3. This comprised the largest cohort examined in this review.  All participants were 
between the ages of forty and seventy, had undergone either surgical or natural menopause for one 
year or greater, and had serum FSH levels of greater than 40 IU/L.  Inclusion criteria required that all 
participants have ultrasound documented increased intima-media thickness (IMT) in at least one 
segment of either carotid artery.  Therapy consisted of 1 mg daily of 17β-estradiol continuously plus 
either 0.25 mg gestodene for daily for twelve days every month or daily for twelve days every third 
month—standard and low progestin groups respectively versus no HRT.  Duration of the study was 
forty eight weeks, and endpoints measured were carotid IMT, total cholesterol, LDL cholesterol, serum 
fibrinogen, and serum FSH at 12, 22, and 48 weeks.  Results of ultrasound analysis of carotid IMT 
actually increased in all groups, and the increase in both HRT groups was greater than the group with 
no HRT.  However, the results were not statistically significant (P>0.2).  Other outcome measures 
including LDL cholesterol and fibrinogen were statistically significantly reduced in both HRT 
treatment groups all with P values of < 0.001.  Overall, this study demonstrated without statistical 
significance that, carotid IMT remained unchanged with HRT versus no HRT and that HRT did lower 
LDL cholesterol and fibrinogen levels, in both treatment groups. 
 Stӧrk et al 11 studied fifty one postmenopausal women who had experienced either natural or 
surgical menopause for more than one year and had serum FSH levels of > 40 IU/L in a prospective, 
randomized, placebo-controlled trial that received a Jadad score of 3.  The average age of participants 
in this study was sixty years old.  Therapy consisted of 1 mg 17β-estradiol daily plus 25 mcg gestodene 
for the last twelve days of either each month or every third month.  To be included, all patients had 
exhibited >1.0 mm carotid IMT at some point of the carotid artery system.  Participants were followed 
for one year.  The endpoint measure was monocyte chemoattractant protein-1 (MCP-1), which is 
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considered a propagator of atherosclerosis.11  The results of this study demonstrated a 16.8% reduction 
in MCP-1 levels among HRT users as compared to placebo, indicating a possible anti-atherosclerotic 
effect among HRT users.  Furthermore, this study concluded that in women stopping HRT, MCP-1 
levels again rose while MCP-1 levels remained lowered in the group continuing HRT. 
 Finally, women with preexisting cardiovascular disease were studied by Hodis et al in the 
Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-
HART).  This randomized, double-blinded, placebo-controlled trial of 226 postmenopausal women 
with a mean age of 63.5 years, who were all younger than seventy five years of age, included only 
participants with a pre-existing coronary artery lesion.  This study received a Jadad score of 5.  
Menopause was confirmed by a serum estradiol level of < 20 pg/mL, and treatment was with 17β-
estradiol 1 mg daily either with or without 5 mg medroxyprogesterone acetate daily versus placebo. 
The primary outcome measure was percent change in coronary artery stenosis measured by coronary 
angiography.  Women in this study were followed for a median of 3.3 years.  The results of this study 
demonstrated no statistically significant difference among the unopposed estrogen, estrogen plus 
progestin, and control groups when comparing progression of coronary artery stenosis.  However, 
interestingly, several other laboratory values were measured and participants in the estrogen and 
estrogen-progestin groups had a statistically significant increase in high density lipoprotein (HDL) 
laboratory values and decreases in cholesterol and LDL values as compared to placebo.  Therefore, this 
study found that estrogen therapy created no change in coronary artery stenosis, however, it is 
important to note that an improvement in lipid profiles was demonstrated in the participants taking 
HRT. 
 Multiple endpoints for cardiovascular disease have been assessed in this systematic review.  
Overall it was found that in three studies atherosclerotic risk was decreased in women on HRT, in three 
studies atherosclerotic risk was increased in women on HRT, and one study indicated no slowing in 
progression of atherosclerosis but decreased risk for cardiovascular disease by improving lipid profiles. 
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Discussion 
 The primary goal of this review was to identify, based on the most current medical literature, 
whether the use of 17β-estradiol for HRT had an effect on various outcomes used to predict the 
progression of atherosclerotic and cardiovascular disease.  The WHI study, a very large randomized 
placebo-controlled trial, demonstrated a possible deleterious effect with regard to the use of estrogen 
replacement therapy on cardiovascular disease.  Though the landmark WHI study, taught us a great 
deal about the safe and effective use of estrogen replacement therapy, it is important to remember that 
the WHI study was not the final word on HRT. It was merely a starting point to identify a myriad of 
questions about HRT that remain without clear answers. 
 For example, in 2007, Rossouw et al12 examined hormone replacement therapy and its effect on 
cardiovascular disease in relation to the initiation of HRT and to the number of years since the onset of 
menopause.  Rossouw et al found that women, who initiated HRT closer to the onset of menopause, 
had a decreased risk for cardiovascular disease when compared to women who initiated HRT further 
from the onset of menopause.  Since participants in the WHI study ranged in age from fifty to seventy 
nine years old, initiating HRT in women closer to the onset of menopause could make a difference 
with regard to cardiovascular risk.  In fact, in November, 2008, the American Committee on 
Gynecologic Practice (ACOG), issued a revised opinion on hormone therapy and heart disease and 
stated: “Hormone therapy use should be limited to the treatment of menopausal symptoms at the 
lowest effective dosage over the shortest duration possible and continued use should be reevaluated on 
a periodic basis.”  This statement also recognized that, “women in early menopause who are in good 
cardiovascular health are at low risk of adverse cardiovascular outcomes and as such should be 
considered candidates for the use of [hormone replacement therapy].”  The final outcome of the WHI 
study even suggested a decreased cardiovascular risk among the women included in the age group of 
fifty to fifty nine years old.13 
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 Another aspect of HRT that must be considered is route of administration.  In the WHI trials, 
all hormones were administered orally.  However, recent evidence has suggested that administering 
HRT transdermally may have a different effect on inflammatory markers, and may decrease 
cardiovascular risk when compared to oral HRT.14.  It is hypothesized that this could be because of the 
fact that estrogen is extensively broken down in the liver via first pass metabolism and by 
administering HRT transdermally this effect may be attenuated.14.  However, much more research is 
needed before a conclusive determination is researched. 
 This systematic review addressed another issue that must be taken into consideration when 
initiating HRT and that is the specific type of HRT that should be prescribed.  In the WHI trials CEE 
and medroxyprogesterone acetate were used for HRT.13  Though CEE does produce beneficial effects 
of HRT such as reducing vasomotor symptoms, from a molecular, biochemical, and pharmacokinetic 
perspective, CEE introduces via breakdown products, types of estrogen such as equilin that are not 
naturally produced, and can lead to various inflammatory responses that are not created by 
biochemically identical 17β-estradiol.15  It is important to note that all of the studies examined in this 
systematic review demonstrated a decrease in cardiovascular risk in patients taking HRT when the 
endpoint measured was a serum biochemical marker.  The studies that demonstrated an increased risk 
for cardiovascular disease in women taking HRT measured endpoints including percent coronary or 
carotid artery stenosis.  This raises the question of whether HRT only improves biochemical profiles 
and does not have a positive effect on endothelial plaque formation, or if the mechanism by which 
estrogen produces a cardioprotective effect is much more complicated than just decreasing plaque 
formation in the arterial system.  Though much more research remains to be done on this topic, it is 
important to note that the bioidentical form of estrogen could possibly be important especially to 
overall secondary effects of estrogen such as the reduction of inflammation and thus various risk 
factors for cardiovascular disease. 
 16 
 Though this review is limited by the fact that a countless number of confounding and 
modifying factors are present when studying a process such as cardiovascular disease progression in 
postmenopausal women, it does help to elucidate many of the topics that remain to be studied with 
regard to the overall and holistic health of postmenopausal women.    
Conclusion 
 Based on the results of this literature review, evidence exists to support the fact that 17β-
estradiol does in fact decrease biochemical markers for atherosclerotic disease including lipid and 
inflammatory markers in women using HRT.  However, the use of 17β-estradiol does not positively 
affect the progression of atherosclerosis in carotid or coronary arteries.  Therefore, 17β-estradiol may 
reduce cardiovascular disease risk but evidence does not suggest that this improvement in lipid profiles 
and inflammation actually affects atherosclerosis progression.  The molecular mechanism by which 
estrogen produces cardioprotection is extremely complex and minimally understood, though research 
suggests that estrogen may act directly as a transcription factor and can produce long term and short 
term effects on vasculature and circulating mediators of cardiovascular disease.4  Many questions 
about the use of HRT in postmenopausal women remain and much research remains to be done 
including research to assess whether 17β-estradiol has a unique effect on cardiovascular risk when 
compared to other forms of HRT.  Research on differential effects of starting HRT at multiple stages of 
menopause, on multiple routes of estrogen administration, as well as research on the usage of different 
molecular forms of estrogen should be conducted in the future to better establish the efficacy and, 
more importantly, safety of HRT for postmenopausal women. 
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TABLE 1: Comparison of trials examining 17β-estradiol for hormone replacement therapy in healthy postmenopausal women 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author Published Study Type Jadad 
Score 
Patients/Population Method for 
determining 
menopause 
Intervention Length 
of 
study 
Endpoint 
measure 
Outcome 
Hodis, 
H.N. 
2001 Randomized, 
double-blinded, 
placebo 
controlled 
5 222 women, 45 years 
or older 
Serum estradiol <20 
pg/mL 
Unopposed micronized 
17β-estradiol 1 mg/d 
2 years Total chol, trigs, 
HDL, LDL, 
glucose, insulin, 
HgbA1C 
Cardiovascular risk 
lower in pt’s on HRT 
Teede, 
H.J. 
2001 Randomized, 
double-blinded, 
placebo 
controlled 
5 59 women, average 
age 61 
2 years 
postmenopause; no 
lab measurement 
17β-estradiol 2 mg/d + 
norethisterone 1 mg/d 
2 years Lipid profiles, 
arterial 
compliance, 
endothelial 
function 
HRT did not 
improve arterial 
indices, but did 
improve lipid profiles 
Thijis, 
A 
2002 Randomized, 
prospective, 
placebo 
controlled 
3 60 women, 45-60 
years old 
Amenorrheic 6 mo-5 
yrs; FSH>20 IU/L, 
estradiol<150 pmol/L 
Micronized 17β-estradiol 
2 mg/d with or without  
trimegestone 0.5 mg/d 
or dydrogesterone 10 
mg/d   
12 
weeks 
Circulating 
acrive platelets 
HRT increased 
platelet activation 
parameters 
Post, 
M.S. 
2003 Randomized, 
prospective, 
placebo 
controlled 
3 60 women, 45-60 
years old 
Amenorrheic 6 mo-5 
yrs; FSH>20 IU/L, 
estradiol<150 pmol/L 
Micronized 17β-estradiol 
2 mg/d with or without  
trimegestone 0.5 mg/d 
or dydrogesterone 10 
mg/d   
12 
weeks 
ADMA level HRT reduced ADMA 
levels with or 
without progestogen 
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TABLE 2: Comparison of trials examining 17β-estradiol for hormone replacement therapy in postmenopausal women with pre-existing cardiovascular 
disease 
 
 
 
 
 
 
Author Published Study Type Jadad 
Score 
Method for 
determining 
cardiovascular 
disease 
Patients/Population Method for 
determining 
menopause 
Intervention Length 
of 
study 
Endpoint 
measure 
Outcome 
Angerer,  
P 
2001 Randomized, 
placebo-
controlled, 
observer 
blinded 
3 Increased IMT 
in >1 segment 
of carotid 
arteries 
321 women, 40-70 
years old 
Natural or 
surgical 
menopause 
for ≥ 1 yr; 
FSH>40 
IU/L 
17β-estradiol 1 mg/d 
+ 0.25 mg gestodene 
for 12 d/mo or 12 
d/every 3rd mo 
48 
weeks 
Carotid 
IMT,chol, 
LDL,fibrinogen 
HRT did not 
affect carotid 
IMT but did 
improve lipid 
profiles 
Stӧ rk, 
S 
2002 Randomized, 
prospective 
3 >1 mm IMT in 
carotid artery 
system 
51 women, average 
age 60 
Natural or 
surgical 
menopause 
for > 1 yr 
FSH>40 
IU/L 
17β-estradiol 1 mg/d 
+ 0.25 mg gestodene 
for 12 d/mo or 12 
d/every 3rd mo 
1 year MCP-1 level HRT 
decreased 
MCP-1 levels 
Hodis, 
H.N. 
2003 Randomized, 
double-
blinded, 
placebo 
controlled 
5 At least one 
coronary artery 
lesion present 
226 women, average 
age 63.5, must be < 
75 years old 
Serum 
estradiol < 
20 pg/mL 
17β-estradiol 1 mg/d 
with or without 5 mg 
medroxyprogesterone 
acetate/d 
Median 
follow-
up 3.3 
years 
Percent 
stenosis in 
coronary 
arteries 
measured by 
angiogram 
HRT did not 
affect 
progression of 
coronary artery 
atherosclerosis 
 21 
Appendix A 
Jadad Score Calculation 
Item Score 
Was the study described as randomized (this includes words such as randomly 
random, and randomization)? 
0/1 
Was the method used to generate the sequence of randomization described 
and appropriate (table of random numbers, computer-generated, etc)? 
0/1 
Was the study described as double blinded? 0/1 
Was the method of double blinding described and appropriate (identical 
placebo, active placebo, dummy, etc)? 
0/1 
Was there a description of withdrawls and dropouts 0/1 
Deduct one point if the method used to generate the sequence of 
randomization was described and it was inappropriate (patients were  
allocated alternately, or according to date of birth, hospital number, etc.)  
0/-1 
Deduct one point if the study was described as double blinded but the  
method of blinding was inappropriate (e.g., comparison of tablet vs  
injection with no double dummy)  
0/-1 
Source: Jadad AR, Moore RA, Carroll D, et al.  Assessing the quality of reports of randomized clinical  
trials: is blinding necessary?  Controlled Clinical Trials.  1996: 17[1]:1-12. 
 
 
 
 
